Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 9/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.43 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700977 | 0.91 | HSD17B10 (0.51) | FFAR1ALDH1A1TBXAS1LMNA | |
| SCHEMBL5731698 | 0.85 | FFAR1 (0.47) | FFAR1KEAP1FFAR4CYP26A1CYP26B1 | |
| SCHEMBL5710694 | 0.84 | FFAR1 (0.46) | FFAR1KEAP1FFAR4TBXAS1LMNA | |
| SCHEMBL5731605 | 0.80 | ALDH1A1 (0.55) | FFAR1ALDH1A1NPSR1L3MBTL1 | |
| SCHEMBL7322408 | 0.79 | NPSR1 (0.42) | FFAR1KEAP1ALDH1A1NPSR1 | |
| SCHEMBL5731941 | 0.78 | NPC1 (0.54) | ALDH1A1LMNA | |
| SCHEMBL3040732 | 0.77 | TBXAS1 (0.50) | ALDH1A1TBXAS1LMNAL3MBTL1 | |
| SCHEMBL5731888 | 0.77 | SMN1; SMN2 (0.49) | FFAR1FFAR4 | |
| SCHEMBL5731392 | 0.76 | MAPK1 (0.47) | FFAR1ALDH1A1LMNA | |
| SCHEMBL5731685 | 0.76 | FKBP1A (0.58) | ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1008346-B1 | NF-kB INHIBITORS CONTAINING BENZOQUINONE DERIVATIVES | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-02-15 | — | — | EP | disclosed |
| US-6943196-B1 | NF-κB inhibitor comprising phenylmethyl benzoquinone as the active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-09-13 | — | — | US | disclosed |
| CN-1212861-C | Preventives or remedies for myocarditis, dilated cardiomyopathy and cardiac insufficiency containing NF-K B inhibitors as the active ingredient | DAIICHI SUNTORY PHARMACEATICAL (JP) | 2005-08-03 | — | — | CN | disclosed |
| CN-1181817-C | NF-KB inhibitors containing as active ingredient phenylmethyl benzoquinone | ��һ��������ҩ��ʽ���� | 2004-12-29 | — | — | CN | disclosed |
| US-6703421-B1 | ADMINISTERING NF-KAPPA B INHIBITOR | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-09 | — | — | US | disclosed |
| US-20040030129-A1 | NF-kappaB inhibitor comprising phenylmethyl benzoquinone as an active ingredient | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2004-02-12 | — | — | US | disclosed |
| CN-1335777-A | Preventives or remedies for myocarditis, dilated cardiomyopathy and cardiac insufficiency containing NF-K B inhibitors as the active ingredient | SUNTORY LTD (JP) | 2002-02-13 | — | — | CN | disclosed |
| EP-1132093-A1 | PREVENTIVES OR REMEDIES FOR MYOCARDITIS, DILATED CARDIOMYOPATHY AND CARDIAC INSUFFICIENCY CONTAINING NF-KAPPA B INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2001-09-12 | — | — | EP | disclosed |
| CN-1262618-A | NF-KB inhibitors containing as active ingredient phenylmethyl benzoquinone | SUNTORY LTD (JP) | 2000-08-09 | — | — | CN | disclosed |
| EP-1008346-A1 | NF-$g(k)B INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT PHENYLMETHYL BENZOQUINONE | SUNTORY LIMITED (JP) | 2000-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030129-A1 | NF-kappaB inhibitor comprising phenylmethyl benzoquinone as an active ingredient | NFKBIA, NFKB2, NFKB1 | FFAR1 2537/4885KEAP1 42/4885CA1 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.